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Translational Systems Pharmacology Studies in Pregnant
Women
Sara K. Quinney1,2*, Rakesh Gullapelli3 and David M. Haas1,2
Pregnancy involves rapid physiological adaptation and complex interplay between mother and fetus. New analytic
technologies provide large amounts of genomic, proteomic, and metabolomics data. The integration of these data through
bioinformatics, statistical, and systems pharmacology techniques can improve our understanding of the mechanisms of
normal maternal physiologic changes and fetal development. New insights into the mechanisms of pregnancy-related
disorders, such as preterm birth (PTB), may lead to the development of new therapeutic interventions and novel biomarkers.
CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 69–81; doi:10.1002/psp4.12269; published online 14 December 2017.
Bioinformatics and systems pharmacology approaches are
enabling us to understand the mechanisms of alterations in
maternal physiology, diseases of pregnancy, fetal develop-
ment, and fetal origins of disease. Pregnancy is a period of
rapid growth and transformation. The integration of data
from genomic, transcriptomic, proteomic, metabolomic, and
other data sources is leading to increased understanding of
the complex interplay among the maternal, fetal, and placen-
tal organs. In addition to exploring normal fetal growth and
development, systems pharmacology techniques can be
used to explore conditions unique to pregnancy, such as pre-
term labor and pre-eclampsia. Additionally, system models
can help us better understand the links between disorders
that occur during pregnancy, such as gestational diabetes,
and the development of future maternal and neonatal
morbidities.
The ultimate aim of systems pharmacology research in
pregnancy is to improve clinical outcomes of both mother
and baby through enhanced clinical care. Many diseases of
pregnancy, including preterm birth (PTB), pre-eclampsia,
and gestational diabetes, are multifactorial but seem to
have a genetic component.1 It is clear that no single bio-
marker can predict the population level risk of these dis-
eases due to their complex etiology. Translational systems
pharmacology provides the means to integrate data from a
large number of studies and variety of data types; spanning
multiple physiological scales (e.g., organ-level, cellular-
level, protein-level, and genomic-level data).2 Systems
pharmacology approaches link biological connections in a
system using mathematical approaches, such as differential
equations and statistical models. Pregnancy creates addi-
tional complexities in the analysis of data, as maternal,
fetal, and even paternal sources of variability must be con-
sidered. Additionally, longitudinal models are needed to
account for the rapid physiologic changes that occur during
pregnancy. Consequently, more sophisticated algorithms
are required when developing systems models of preg-
nancy and pregnancy disorders.
The potential impact of translational systems pharmacol-
ogy models in understanding the maternal-fetal interplay
and improvement of therapeutic opportunities to improve
pregnancy outcomes is great. However, as with other areas
of research, the incorporation of large data analysis in
obstetrics lags behind other fields (Figure 1). Less than
2% of human genomic and proteomic studies and 3.5% of
metabolomic studies recorded in PubMed are related to
obstetrics. Using preterm labor as an example, this review
explores the need for translational systems pharmacology
modeling in obstetrics, challenges faced by researchers,
and opportunities for future advancement.
Physiologic changes in pregnancy
Women who develop either acute or chronic disease may
continue to take a variety of medications throughout gesta-
tion. In addition, pharmaceutical intervention may be
required for pregnancy-induced disorders. However, infor-
mation on pregnancy-induced changes in the pharmacoki-
netics and pharmacodynamics is unavailable for many
drugs.
Pregnancy brings a time of rapid physiologic change, not
only for the developing fetus but also to the mother. These
physiological changes usually begin in early weeks of ges-
tation are amplified in the third trimester of pregnancy and
impact nearly all maternal systems. Adaptations in the car-
diovascular system, respiratory system, hepatic metabo-
lism, renal excretion, and gastrointestinal system can affect
drug pharmacokinetics. The activities of cytochrome P450
(CYP)3A4, CYP2D6, and CYP2C9 increase during preg-
nancy, leading to higher clearance of substrates of these
enzymes.3,4 On the other hand, drugs metabolized by
CYP1A2 and CYP2C19 may require lower doses during
pregnancy due to the reduced activity of these isoen-
zymes.3,4 The decreased concentrations of albumin and
a1-acid glycoprotein during pregnancy can alter the protein
binding of drugs.5 Glomerular filtration rate begins to
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increase as early as 6 weeks gestation, and leads to
increased creatinine clearance and renal clearance of
drugs. Furthermore, increased cardiac output beginning at
8–10 weeks’ gestation causes an increase in blood flow to
the uterus and kidneys, which may also increase the renal
clearance of drugs. A pregnancy-induced increase in
plasma and blood volume starting at 6–10 weeks’ gestation
leads to hemodilution, which can alter the distribution of
drugs to red blood cells.4 Increased progesterone, estro-
gen, cortisol, placental lactogen, and other hormones dur-
ing pregnancy also lead to physiologic changes that can
also affect the pharmacodynamics of drugs. For instance,
changes occur in coagulation and fibrinolytic pathways
leading to hypercoagulation, increased insulin resistance
can lead to carbohydrate intolerance, leptin production
increases, and thyroid hormone control is challenged by
estrogenic increases in thyroid binding globulin.6
Physiologically based pharmacokinetic models of
pregnancy
To date, systems pharmacology modeling in pregnancy has
largely been limited to the use of physiologically based
pharmacokinetic (PBPK) modeling to estimate changes in
drug disposition. Olanoff & Anderson7 were among the first
to use PBPK modeling in pregnancy to describe tetracy-
cline disposition in rats. Initial use of PBPK models in preg-
nancy was for the prediction of fetal risk assessment.8
More recently, PBPK models have been used to describe
changes in the pharmacokinetics of therapeutic agents dur-
ing pregnancy.
A variety of structural models, demonstrating a wide
range of complexity, have been used for pregnancy PBPK
models. The majority of models have used a full maternal
PBPK structural model, although some have used reduced
models that isolate organs of interest (e.g., liver and
placenta/fetalunits).9,10 The structures applied to the fetal-
placental unit are more varied and include combined
placental-fetal compartment11; the separation of fetus and
placenta into two distinct compartments10,12; addition of an
amniotic fluid compartment13; and full fetal PBPK models
with separate placental compartments.14
In addition to the inclusion of fetal/placental compart-
ments, these models are also parameterized to describe
the physiological changes that occur during pregnancy.
Because pregnancy is a fluid state with rapid changes in
maternal, placental, and fetal physiology, it is important to
account for the longitudinal changes in blood flows, organ
composition, and functional activity during pregnancy. Ini-
tially, PBPK models of pregnancy focused on a snapshot of
gestation, often describing a few hours or days of expo-
sure.9 These models typically used static parameter mod-
els, describing the gestational age of interest. In more
recent years, pregnancy PBPK models have incorporated
dynamic changes in maternal and fetal physiology to esti-
mate exposure across gestation.11,15 Although the majority
of published pregnancy PBPK models have been user-built,
the commercial PBPK modeling software Simcyp (Certera)
has released a pregnancy population model that utilizes a
combined placental-fetal compartment and allows for longi-
tudinal changes in number of key physiologic parameters
across gestation.11,15
One limitation in the development of pregnancy PBPK
models is the availability of data regarding changes in phys-
iological parameters affecting drug disposition and clinical
pharmacokinetic data for model verification. Several groups
have cataloged a number of physiological changes across
gestation.4,16,17 However, these data often come from a
variety of literature sources, which may have been obtained
using inaccurate methods.17 In some cases, these data are
based on studies in nonpregnant women or animals. Some
parameters may be impacted by study design, leading to
inconsistencies in the literature. For instance, hepatic blood
flow in pregnancy has been reported to increase in some
studies but remain constant in others.18,19 In addition, these
studies often do not account for correlations among param-
eters, such as the relationship between albumin concentra-
tion and blood volume, or include covariates, such as
Figure 1 PubMed citations per year relating to (a) genomic,
(b) proteomic, and (c) metabolomic studies in pregnancy (gray
line). For comparison, the black line represents all genomic, pro-
teomic, or metabolomics studies in PubMed and the dashed line
indicates those studies relating to oncology.
Systems Pharmacology in Pregnancy
Quinney et al.
70
CPT: Pharmacometrics & Systems Pharmacology
gravidity.17 Physiologic data from pregnancy, especially with
respect to fetal and placental makeup, are often limited by
the gestational age range. For instance, fetal blood volume
is well-defined only from 21–35 weeks of gestation.17
Although PBPK modeling is useful to predict the pharma-
cokinetics of drugs in pregnancy, it can also aid in under-
standing the physiologic changes that occur during
pregnancy. This approach has been used to better under-
stand the fluctuations in drug metabolizing activity during
pregnancy. For instance, although it has long been recog-
nized that the clearance of CYP3A substrates is increased
in pregnancy,3 PBPK modeling allows for the incorporation
of changes in plasma protein binding, tissue volumes, blood
flow, and renal clearance to more accurately estimate the
change in CYP3A activity during pregnancy. Interestingly,
we and others have demonstrated that hepatic, but not gut
wall, CYP3A activity seems to be increased during preg-
nancy.10,11 This approach has also been used to estimate
the altered activity of other CYP450 enzymes during preg-
nancy.20 However, verification of pharmacokinetic models in
pregnancy is complicated by a lack of clinical drug concen-
tration data from pregnant women. Pharmacokinetic studies
in pregnancy are restricted due to ethical or logistic issues.
Fetal concentrations are often only available from umbilical
venous blood collected at delivery. Although the maternal
plasma to umbilical vein concentration of drugs has often
been used to estimate fetal drug exposure, this ratio is
affected by other disposition (i.e., ADMET) properties of the
drug and time of sample collection postdose. Obtaining
high-quality clinical pharmacokinetic data on drugs from
women throughout all stages of gestation is necessary to
improve therapeutic outcomes in pregnant women.
Expanding systems pharmacology in pregnancy
beyond PBPK
Although PBPK models have provided a means to evaluate
longitudinal changes in drug exposure during pregnancy,
virtually no group has extended systems pharmacology
approaches to improve our understanding of pregnancy-
associated diseases. During pregnancy, the maternal body
undergoes immense adaptation to sustain fetal develop-
ment, growth, and parturition. This requires remarkable
integration and communication between the fetus, placenta,
and mother. As described above, nearly every aspect of
maternal physiology is impacted by pregnancy, leading to
major changes in expression and function of genes, pro-
teins, and organ systems. In the past, many of these
changes have been studied in isolation, based on available
technological capabilities.21 However, advanced technology
now enables high-dimensional study of genes, proteins, and
other analytes. Systems pharmacology models are needed
to integratively characterize the longitudinal changes in the
genome, transcriptome, proteome, metabolome, lipidome,
etc., throughout pregnancy and directly relate these
molecular-level data with organ-level changes and outcomes,
such as PTB. A first step in developing systems pharmacol-
ogy models of pregnancy-related diseases is understanding
the mechanisms of normal fetal development and parturition.
One challenge faced by obstetrics researchers is the
analysis of large, longitudinally collected datasets. The
majority of omics studies compare data obtained at a single
time from an individual. However, especially with the rapid
developmental changes occurring during gestation, it is
important to understand the longitudinal changes in omics
data across pregnancy. Many studies have evaluated longi-
tudinal changes of a single factor (e.g., organ volume, blood
flow, or gene expression) in maternal and fetal physiology
across pregnancy. A number of meta-analyses are available
to inform parameterization of quantitative models across
pregnancy.4,16,17 Yet, few studies have evaluated longitudi-
nal changes in large datasets throughout gestation. In part,
this is due to lack of informatics and statistical tools to eval-
uate such data.22
Romero et al.21 recently conducted a proteomics study
that sampled plasma at 3–6 time points across gestation
from 43 women with normal deliveries. A multiplex Slow-Off
Rate Modified APtamers (SOMAmer) platform (Somalogic,
Boulder, CO) was used to evaluate the abundance of
>1,125 plasma proteins. They identified 112 proteins that
exhibited >1.5-fold change between 8 and 40 weeks of
gestation that had false discovery rate-adjusted values (q-
values) of P< 0.1. Longitudinal changes in protein abun-
dance were modeled using a cubic spline function and
hierarchical clustering demonstrated six distinct pattern
changes: increasing abundance at increasing rate (n521),
constant rate (n5 23), and decreasing rate (n527) across
gestation and decreasing abundance at increasing rate
(n5 8), constant rate (n5 16), and decreasing rate (n5 17)
across gestation. The highest-fold changes were observed
for placental growth factor; pregnancy-associated plasma
protein A (PAPP-A); sialic acid-binding immunoglobulin type
lectins (Siglec-6); glypican-3; CC-motif (CCL); carbonic
anhydrase 6; prolactin (PRL); interleuken-1 receptor 4 (IL-1
R4); and dual-specificity mitogen-activated protein kinase 4
(MP2K4; Table 121). Many of these proteins are involved in
angiogenesis, embryogenesis, and immune regulation.
Protein-protein interaction network mappings and functional
analyses identified the proteins with the greatest change
across gestation involved in general defense response;
defense response to bacteria and fungi; germ cell migra-
tion; proteolysis; and leukocyte migration.21
Preterm birth
PTB affects 9.6% of pregnancies annually and is a major
cause of neonatal morbidity and mortality worldwide.23
Although environmental factors, such as smoking, obesity,
and maternal stress increase the risk of PTB, maternal
genomics have been linked to 15–25% of PTBs and fetal
genomics with around 10% of PTBs.24 The etiology of PTB
is multifactorial and complex owing to variations in the
physiology of pregnancy women, gestational age, interac-
tions between maternal and fetal genome, and environmen-
tal factors. Currently, the best clinical approach for
prediction of PTB is the medical history, in which the recur-
rence risk may increase up to 15% with each previous
PTB.25 Moreover, available data suggest that the increased
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risk of PTB is often inherited across generations.1 Geno-
mic, transcriptomic, proteomic, and metabolomic studies of
PTB are providing enhanced insight into the various mech-
anisms underlying the pathophysiology of PTB. It is hoped
that these studies will lead to the identification of early bio-
markers of PTB that would enable earlier intervention and
development of novel therapies to prevent and treat PTB.
Below, we review the status of genomic, proteomic, and
metabolomic studies in PTB.
Genomic studies of PTB
The majority of genomic studies of PTB have used targeted
approaches, often based on results of previous studies,
pathway analyses, or biological plausibility. Inflammatory
factors have been most commonly associated with
increased risk of PTB, including single nucleotide polymor-
phisms (SNPs) in IL-1, IL-4, matrix metalloproteinases, nat-
ural killer cells, and toll-like receptors. However, none of
these factors consistently predicts the occurrence of PTB.26
This deficiency of targeted studies is anticipated for a disor-
der such as PTB, where there are complex patterns of
inheritance and multiple factors contribute to its pathophysi-
ology.27,28 Limiting investigations to just a few targeted
genes, proteins, or metabolites restricts the information
obtained to select pathways and not the system as a whole.
Therefore, candidate gene studies are likely to miss impor-
tant contributors outside of the known pathways, as well as
the potential for interaction among different genes, proteins,
or environmental factors.
Although a number of genomewide association studies
(GWAS) have been conducted evaluating the timing of
delivery, none have identified SNPs that are robustly asso-
ciated with preterm delivery (Table 229–34). A number of
factors may contribute to the lack of association observed
in these studies, including limited sample size, ethnic differ-
ences, and heterogeneity in the phenotype definition.
Although PTB is a multifactorial process, with distinct pheno-
types, such as infection/inflammation, uterine overdistention,
hemorrhage, and cervical dysfunction,35 the majority of
genomic studies only classify PTB by gestational age at
delivery. Even this cutoff point can vary among and even
within studies. Standardized definitions of PTB phenotypes
and more precise categorization of subphenotypes will lead
to improved understanding of the various etiologies of PTB.
Capece et al.36 recently conducted a meta-analysis to differ-
entiate pathways associated with PTB due to preterm prema-
ture rupture of membranes (PPROMs) or spontaneous PTB
(sPTB) with intact membranes. They included data from 15
studies of 3,600 women on 2,175 SNPs in 274 genes and
found 248 SNPs of 102 genes that were statistically associ-
ated with sPTB with intact membranes, and 39 SNPs in 32
genes statistically significantly associated with PPROM.
Although ingenuity pathway analysis identified that the top
four molecular and cellular functions (cell-to-cell signaling
and interaction, cellular movement, lipid metabolism, and
small molecule biochemistry) were common to both groups,
more detailed interrogation identified distinct differences.
Spontaneous PTB was found to be more associated with
autoimmune/hormonal regulation, including the glucocorti-
coid signaling pathway, whereas etiologies of PPROM
included hematologic/coagulation function disorder, collagen
metabolism, matrix degradation, and local inflammation.36
Although overlap was observed in pathways associated with
PPROM and sPTB, this study demonstrated that they also
have distinct pathophysiologies. These effects may be
diluted when studies of both phenotypes are grouped
together.
Proteomic studies of PTB
Proteomics could be one of the most reliable “omics” stud-
ies and serves as an alternative, unbiased approach for
biomarker discovery. As proteins play a pivotal role in
understanding the etiology and pathogenesis of PTB and
spontaneous preterm deliveries, rich information on the bio-
logical mechanisms underlying PTB can be gleaned from
proteomic analyses. The majority of the proteomic studies
Table 1 Proteins exhibiting the greatest fold-change across gestation in normal pregnancy
Protein Gene symbol Fold-change Direction of change Trend across pregnancy
Glypican 3 GPC3 26.04 Increasing Decreasing rate
Siglec-6 SIGLEC6 16.92 Increasing Increasing rate
PlGF PGF 14.46 Increasing Decreasing rate
CCL28 CCL28 6.25 Increasing Decreasing rate
Carbonic anhydrase 6 CA6 5.79 Increasing Decreasing rate
PRL PRL 5.75 Increasing Constant rate
IL-1 R4 IL1RL1 5.49 Increasing Increasing rate
MP2K4 MAP2K4 5.23 Decreasing Constant rate
PAPP-A PAPPA 5.18 Increasing Decreasing rate
LEAP-1 HAMP 4.32 Decreasing Decreasing rate
RET RET 4.15 Increasing Decreasing rate
TFF3 TFF3 4.31 Increasing Decreasing rate
CCL, CC-motif; IL-1, interleukin; LEAP-1, liver-expressed antimicrobial peptide 1; MP2K4, mitogen-activated protein kinase 4; PAPP-A, pregnancy-associated plasma
protein A; PlGF, placental growth factor; PRL, prolactin; RET, ret proto-oncogene; Siglec, sialic acid-binding immunoglobulin type lectins; TFF3, trefoil factor 3.
Adapted from Romero et al.,21 Am. J. Obstet. Gynecol. (2017).
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in PTB are based on either changes in the concentration of
a protein/peptide or in their differential expression between
the preterm and control groups indicating a diagnostic and
or predictive factor for PTB.37 Studies have explored the pro-
teomes of PTB in maternal serum, plasma, fetal and amniotic
fluids with or without intra-amniotic inflammation/infection,
and preterm rupture of membranes at an early stage of preg-
nancy before the onset of symptoms, during the second and
third trimesters of pregnancy (Table 338–45). Several high-
throughput analytical techniques (e.g., gas chromatography-
mass spectrometry (GC-MS), liquid chromatography-mass
spectrometry (LC-MS), 1hydrogen nuclear magnetic reso-
nance (1H-NMR), ultra-performance liquid chromatography
(UPLC-MS), immunosorbent assays, iTRAQ matrix-assisted
desorption/ionization-mass spectrometry (MALDI-MS)) have
been used in proteomic studies to identify as well as mea-
sure the biomarkers indiscriminately.
Although sampling of amniotic fluid carries inherent risks
to the fetus, it provides the opportunity to evaluate the fetal
environment during pregnancy. Proteomic profiling of amni-
otic fluids in patients with PTB with or without intra-amniotic
infection/inflammation (IAI) using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) was studied by
Romero et al.46 The study identified 309 unique high-
confidence proteins that were associated with PTB with IAI.
Many proteins, including thymosin-like 3, leukocyte elastase
precursor, and 14-3-3 protein isoforms, were upregulated in
patients with PTB and IAI. They also identified 82 differently
expressed proteins in the amniotic fluid of pregnant patients
who delivered preterm without IAI, including latent-transforming
growth factor beta-binding protein isoform 1L precursor,
mimecan precursor, and resistin. This study provides further
evidence of unique mechanisms responsible for different
phenotypes of PTB. Other studies have evaluated potential
Table 2 Genomewide studies of PTB or gestational age at delivery
Subjects Platform Findings Replication Reference
Boston Birth Cohort; 698 PTB;
1,035 term controls
Illumina HumanOmni2.5-4v1 or
8v1 arrays; 2,160,368 SNPs
analyzed
Rs11161721 (COL24A1) in
normal weight African
American mothers associ-
ated with an increased risk
of PTB (AA genotype
1.8–2.0 times higher risk)
but risk of PTB tended to
decrease in overweight
mothers
GWAS of prematurity and its
complication (dbGaP
#phs000353.v1.p1), and the
NICHD Genomic and
Proteomic Network for PTB
Research (dbGaP
#phs000714.v1.p1). Results
replicated in African
American subjects but not
white subjects
29
Norwegian Mother and Child
Cohort (MoBa); 1,743
maternal and 1,109 fetal
samples
a) 513,273 autosomal; 12,304
X chromosome SNPs
a) No significant SNPs
identified
Not conducted 30
b) Gene-set enrichment 1,541
genes
b) Maternal genes in labor-
initiated labor were enriched
for pregnancy related gene
sets (infection, inflammation,
immunity)
GPN for PTB research; 1,025
sPTB <34 weeks; 1,015
controls
Affymetrix SNP array 6.0;
maternal and fetal DNA
analyzed
No maternal SNPs reached
statistical significance; fetal
rs17527054 (major histo-
compatibility complex,
OR5 0.39; P5 2.7E-12) and
rs3777722 (RNASET2,
OR5 0.57; P5 1.4E-10)
were significant
293 cases, 200 controls; did
not validate fetal SNPs. No
overlap in the top 10 mater-
nal and fetal gene sets
31
Norwegian Mother and Child
Cohort (MoBa) and Danish
National Birth Cohort; 1,535
PTBs; 1,487 controls
Illumina Human660W-Quad
BeadChip analysis of
X-chromosome
No maternal or fetal SNPs
reached significance after
correction for multiple
comparisons
SNPs approaching significance
were not replicated in
validation cohort from United
States, Argentina, and
Denmark
32
Norwegian Mother and Child
Cohort (MoBa) and Danish
National Birth Cohort; mater-
nal: 2,128 PTBs; 1,868 con-
trols; fetal: 1,763 PTBs;
1,543 controls
Illumina Human660W-
Quadv1_A including 135
mitochondrial SNPs
No SNPs were significant after
correction for multiple
comparison
88 SNPs were included in a
meta-analysis of both
cohorts. None found
significant
33
Finnish cohorts; 165 PTBs;
163 controls
Affymetrix SNP array 6.0; 150
genes selected for analysis
based on evolutionary
mapping
91 SNPs, including 8 of 10
SNPs in FSHR were signifi-
cant (P< 0.01) before cor-
recting for multiple
comparisons
299 cases and 620 controls
from European American,
African American, or Hispanic
(Mexican) American cohorts
genotyped for FSHR. 3 SNPs
significant in African
Americans after correcting for
multiple comparisons
34
FSHR, follicle stimulating hormone receptor; GPN, Genomic and Proteomic Network; GWAS, genomewide association study; NICHD, National Institute of Child
Health and Human Development; OR, odds ratio; PTB, preterm birth; SNPs, single nucleotide polymorphisms; sPTB, spontaneous preterm birth.
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Table 3 Proteomic studies of preterm birth
Sample Proteomic analysis Key proteins affected (OR) Key pathways Reference
Plasma collected 10–15 weeks
GA in 41 women experienc-
ing PTB and 88 term con-
trols with uncomplicated
spontaneous vaginal delivery
in the Denver Complement
Study
SOMAscan proteomic assay;
1,129 proteins
Coagulation factors IX ab (158
OR) and IX (281); factor B
(41); PECAM-1 (40.4); com-
plement factor H (26); SAP-
component (17.8); VEGF
SR2 (10.5); cathepsin Z
(6.6); GHR (6.4); ficolin-3
(5.6); ATS15 (4.9);
P-cadherin (4.8); etc
Complement cascade; immune
system; clotting cascade
38
Serum circulating micropar-
ticles at 15–17 weeks GA
from 14 sPTB and 12 term
control primigravida and 10
sPTB and 12 term second
pregnancies
LC-MS analysis generating
500,000 peptide signals
a1-antitrypsin (1.33 OR); anti-
thrombin III (1.36); a2-
macroglobulin (2.07), a1B-
glycoprotein (1.33); albumin
(1.34); apolipoproteins L1
(3.12) & D (1.32); AZGP1
(1.44); IGG kappa (0.48);
serotransferrin (1.37); IGHM2
(2.22); complement factors
C1R (0.76) C3 (0.8),C4-B
(0.74), & H (0.7), etc
Antigen presentation, humoral
immune, and inflammatory
pathways
39
Serum from 19–24 weeks
(n5 35), or 28–32 weeks
(n5 16) GA from 51 PTBs
and 51 matched controls in
the Genomic and Proteomic
Research Network for
Preterm Birth Research
Targeted proteomics using
SILAP; shotgun proteomics
using LC-MS/MS on pooled
samples
Serpin B7 concentrations
1.5-fold higher in women
with subsequent PTBs
Matrix degradation 40
Serum obtained at 24 weeks
GA from 40 subjects with
sPTB and 40 uncomplicated
controls
Capillary liquid chromatography
electrospray ionization time-
of-flight mass spectrometry of
low molecular weight proteins
Inter-alpha-trypsin inhibitor
heavy chain 4 protein (OR
2.4–8.76)
Not performed 41
Circulating microparticles iso-
lated from plasma collected
10–12 weeks gestation from
25 singleton PTBs 34
weeks and 50 matched con-
trols Brigham and Women’s
Hospital, LIFECODES cohort
Targeted LC-MRM of 132
proteins (Biogenesis AG)
62 proteins “robust power of
detecting” sPTB
Inflammation, wound healing,
coagulation cascade, steroid
metabolism
42
Serum from 5 nonpregnant
women; 5 women with pre-
term labor leading & preterm
delivery; 5 with preterm labor
with term delivery; 5 with term
labor resulting in delivery; 5 at
term with contractions Univer-
sity Hospital, Cincinnati, OH
SELDI; Matrix-assisted laser
desorption ionization
(MALDI); 2-dimensional
electrophoresis
All proteomic techniques identi-
fied differentially expressed
between groups. However,
proteins were not identified
Not performed 43
Serum collected from 48
women with sPTB <34
weeks; 62 women who
experienced preterm labor
with delivery 34 weeks
(PTL) at the University of
Washington
MALDI-TOF-MS and 2D-LC
MS/MS analysis of
glycoproteins
52 proteins differentially
expressed between PTL and
PTB (e.g., coagulation factor
VII (5.4 fold-change)); sero-
transferrin (3.7); protein
S100-A9 (5.6); alpha-enolase
(-6.5); serum amyloid-P com-
ponent (4.5); tenascin
C (-4.89); cell adhesion mole-
cule L1-like protein (-5.6)
Complement and coagulation
cascade; inflammation and
immune response; fetal-
placental development;
extracellular matrix
44
Serum collected 16–17 weeks
EGA from 10 women with
PTB at 34–37 weeks and 10
term controls; Rostov
Research Institute of Obstet-
rics and Pediatrics, Rostov-
on-Don, Russia
MALDI-MS following fraction-
ation of serum samples
using magnetic beads with
reverse phase (MB-HIC C8),
metal-affine (MB-IMAC Cu),
and weak cation-exchange
(MB-WCX) surfaces
according
25 proteins showed differential
expression (presence/
absence), including transgelin-
2, b2-glycoprotein-1, SOD1,
gelsolin, VEGF-A, prolactin-
inducible protein, E-cadherin,
endoplasmin, bikunin, fibrino-
peptide B, lipocalin-1
Antioxidant enzymes, chaper-
ons, cytoskeleton proteins,
cell adhesion molecules,
angiogenesis, proteolysis,
transcription, and
inflammation
45
2D-LC MS/MS, 2-dimentional liquid chromatography tandem mass spectrometry; EGA, estimated gestational age; GA, gestational age; GHR, growth hormone
receptor; LC/MRM, liquid chromatography/multiple reaction monitoring; LC-MS/MS, liquid chromatography tandem mass spectrometry; MALDI, matrix-assisted
laser desorption ionization; MALDI-MS, matrix-assisted desorption/ionization-mass spectrometry; MALDI-TOF-MS, matrix assisted laser desorption/ionization-
time of flight-mass spectrometry; MS, mass spectrometry; OR, odds ratio; PTB, preterm birth; PTL, preterm labor; SAP, serum amyloid P; SELDI, surface-
enhanced laser desorption ionization; SILAP, stable isotope-labeled proteome; VEGF, vascular endothelial growth factor.
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proteomic biomarkers in cervical vaginal fluid (CVF). Pereira
et al.47 used multidimensional LC-MS/MS, multidimensional
protein identification technology, and fluorescence two-
dimensional differential in-gel electrophoresis techniques to
identify and quantify the novel protein biomarkers of PTB in
the CVF. Using multidimensional protein identification tech-
nology analysis, they discovered 205 proteins in CVF,
whereas two-dimensional differential in-gel electrophoresis
identified 17 proteins in PTB and spontaneous PTB.47
Identification of biomarkers in maternal serum or plasma
provides a less invasive approach to identify women at risk
for PTB. Gunko et al.48 used mass spectrometric profiling
of maternal serum to identify the proteomic predictors of
PTB. Their findings detected changes in the production of
25 proteins with various regulatory functions namely prote-
olysis, angiogenesis, inflammation processes, transcription,
and binding and transportation of various ligands that can
predict the PTB as early as during the second trimester of
pregnancy.45 Lynch et al.38 performed a longitudinal cohort
study using SOMAscan proteomic assay method to measure
the protein pathways in plasma among preterm deliveries
and controls. The study identified complement cascade, the
immune system, and the clotting cascade as top pathways to
be associated with PTB, as coagulation factors IX and IX ab,
Factor H, and Factor B were associated with increased risk
of preterm delivery. Despite having heterogeneous study
population and lack of validation of the findings, the authors
concluded that plasma protein profiling at 10–15 weeks of
gestation can predict the PTB later in pregnancy. Parry
et al.40 used shotgun and targeted proteomic techniques
combined with stable isotope labeling of amino acids in cell
culture to identify proteins in maternal serum. They found
that higher serpin B7 concentrations in maternal serum
obtained 28–32 weeks gestation were associated with
shorter interval to delivery and lower gestational age at
delivery.
Metabolomic studies of PTB
Like other omic approaches, metabolomics does not
depend on a specific hypothesis but provides an unbiased
analysis of the phenotypic makeup of a typical cell, tissue,
or organ by virtue of its ability to quantify multiple metabo-
lites. Metabolomic studies profile low molecular weight
metabolites in a given biological sample to generate an all-
inclusive spectrum. The majority of metabolomic studies for
PTB have utilized maternal serum, plasma, amniotic fluid,
urine, and CVF using both targeted and nontargeted
approaches. A large variety of analytical technologies have
been utilized, including 1H-NMR spectroscopy,48,49 GC-
MS,50 LC-MS,51 gas and liquid chromatography and mass
spectroscopy (GC-LC-MS),52 UPLC-MS,53 and ultra-high
performance liquid chromatography coupled to mass spec-
trometry (UHPLC-MS).54 Each analytic method may target
different metabolites. In addition, data may be reported in a
variety of formats and any number of downstream informat-
ics and statistical analyses may be utilized. Thus, it may be
difficult to compare data between studies.
Grac¸a et al.55 used NMR to analyze amniotic fluid and
an untargeted UPLC-MS to analyze the second trimester
amniotic fluid and maternal urine to identify the maternal
biomarkers and their effects on fetal malformations, PTB,
and gestational diabetes and compared women with PTB
and controls. Despite the limitations of sample size and
technology they used, their findings revealed the existence
of different levels of amino acids between the two groups.
Heazell et al.53 used UPLC-MS to identify the differences in
maternal and fetoplacental metabolites in maternal serum
in third trimester pregnancies compared with controls. The
study found that 98 metabolites, including free fatty acids,
sterol lipids, glycerolipids, sphingolipids, progesterone, and
vitamin D metabolites have differed between normal and
poor pregnancy outcomes. Their findings are helpful in pre-
dicting the potential molecular mechanisms associated with
pregnancy complications linked with placental dysfunction
in the third trimester.53 Romero et al.52 used mass spec-
trometry (MS), using both gas and liquid chromatography
data for a retrospective study, to identify the potential predic-
tor metabolites for PTB in amniotic fluid collected between
22 and 35 weeks gestation, regardless of the presence or
absence of intra-amniotic infection/inflammation. Although
lacking confirmatory studies, the researchers reported that
carbohydrates, amino acids, and xenobiotic compounds
among the top predictors to identify the patient at risk for
PTB. Table 448–52,54 provides information on these and
other serum metabolomics studies relating to PTB.
Although metabolomic studies have provided generalized
approaches to identify the high-risk pregnant women
through various biochemical risk factors, several limitations
still exist that limit their utility as predictive biomarkers of
PTB. High intra-individual variabilities, biomarker redun-
dancy, overlapping biochemical and metabolic pathways,
and the lack of qualitative and quantitative confirmatory
studies are hindering the accurate prediction of PTB. A sys-
tematic review revealed that 116 biomarkers have been
identified for their role in PTB, but no single biomarker is
able to accurately and reliably predict the risk of PTB.56
Pharmacogenomic studies of drugs used in PTB
Studies of drug therapies in pregnant women are often lim-
ited due to logistic and ethical concerns. Only a handful of
studies have evaluated the role of pharmacogenomics in
interindividual variability in response. We have previously
reviewed the status of personalized medicine and pharma-
cogenomic data available for drugs used in a number of
pregnancy conditions.57,58 Below, we summarize the data
available for drugs commonly administered to women expe-
riencing preterm labor.
Antenatal corticosteroids have been prescribed to induce
fetal lung maturation in women with threatened preterm deliv-
ery for decades.59 The dosing regimen of betamethasone
used today is identical to that administered by Liggins &
Howie59 in their 1972 clinical study. Although shown to
improve neonatal outcomes, including respiratory distress
syndrome (RDS), there is still wide variability in response.60
Systems pharmacology studies may provide insight into
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individuals who may benefit from increased or decreased
dosing of betamethasone. We have conducted a series of
studies evaluating pharmacogenomic determinants of neo-
natal respiratory response to antenatal corticosteroids,
reporting results from a study of 109 women who delivered
117 infants of whom 64 were diagnosed with RDS. Mater-
nal CYP3A5, maternal NR3C1 (rs4142347), fetal ADCY9
(rs2230739), and fetal CYP3A7*1E (rs28451617) were sig-
nificantly associated with neonatal RDS in a multivariable
analysis that adjusted for maternal age, maternal and
paternal race, estimated gestational age (EGA) at delivery,
birthweight, infant sex, cesarean delivery (vs. vaginal deliv-
ery), EGA at first dose of betamethasone, and the pres-
ence of chorioamnionitis.61 Subsequently, we have reported
that betamethasone clearance is increased in women who
are CYP3A5 expressers.62 In a separate report, 867 SNPs
in 68 glucocorticoid response genes were evaluated for
associations with neonatal RDS. Interestingly, the most
influential SNPs on RDS outcomes seemed to be involved
in a variety of physiological pathways. Maternal SNPs were
related to maintaining chromosome stability (CENPE), cell
cycle regulation and progression (AURKA), cell adhesion,
motility, and differentiation (CD9), and signaling (GLXR).
Significant fetal SNPs included structural collagen (COL4A3);
regulation of hematopoietic cell proteoglycan (SRGN);
chromosome stability maintenance (CENP1); and cell dif-
ferentiation (BHLHE40).63 Ongoing studies will further
probe the relationships among pharmacokinetics, pharma-
cogenomics, and clinical outcome in neonates exposed to
antenatal corticosteroids.
Antitocolytic therapy to stop preterm labor is common but
success varies and no agent has emerged as a gold stan-
dard.64,65 Many commonly used tocolytics are substrates of
polymorphic enzymes or target polymorphic receptors.
However, there is a paucity of research evaluating factors
contributing to the interindividual variability in response to
antitocolytic agents.
The b2 adrenergic receptor agonist ritodrine is the only
US Food and Drug Administration-approved drug for pre-
term labor tocolysis. However, side effects and limited effi-
cacy of ritodrine and other b2 adrenergic receptor agonists,
such as terbutaline and hexoprenaline, have led the US
Food and Drug Administration and the European Medicines
Agency to issue warnings and limit prolonged use of these
agents in recent years.66,67 Although results are not consis-
tent, some b2 adrenergic receptor genotypes may be pro-
tective against preterm delivery.68,69 Women who are
homozygous for Arg16 in b2 adrenergic receptor had
improved pregnancy outcomes following hexoprenaline in
one study.70
Nifedipine and other calcium channel blockers have been
shown to have favorable efficacy and safety profiles for the
acute treatment of preterm labor.71 Nifedipine undergoes
metabolism by CYP3A enzymes in the liver and gastroin-
testinal tract. Nifedipine clearance is increased in preg-
nancy, due to increased CYP3A.3,10,11,72,73 Plasma
concentrations of nifedipine also demonstrate high interindi-
vidual variability (30–70%) among pregnant women. Stud-
ies of nifedipine in pregnant women have found that
CYP3A5 genotype and concomitant administration of
Table 4 Metabolomic studies of PTB
Sample Metabolomic analysis Key findings Reference
Amniotic fluid and maternal
serum 35 PTBs; 35 term
controls
UHPLC-TOF-MS and UHPLC-
MS-MS
Differences detected among groups in 13
lipids in maternal serum; differences in a
number of biomarkers, including pyru-
vate, glutamic acid, inositol in amniotic
fluid and hypoxanthine, tryptophan, and
pyroglutamic acid in serum
54
Amniotic fluid from African
American women; 25 PTBs;
25 controls
GC-MS; LC-MS/MS performed
by Metabolon
116 metabolites were significantly different
among groups; common pathways
involved in liver function, fatty acid, and
coenzyme A metabolism, and histidine
metabolism
51
CVF in 82 women with threat-
ened, but not confirmed PTL
1H-NMR and enzyme-based
spectrophotometry
Elevated CVF acetate was predictive of
PTB but did not add predictive accuracy
over ultrasound cervical length and fetal
fibronectin
48
CVF collected at 20 weeks
from 30 sPTB cases and 30
controls
GC-MS of 112 compounds No significant differences between PTB
cases and normal term controls
50
88 sPTB and 275 controls
urine samples from late first
trimester
1H-NMR spectroscopy of 34
metabolites
sPTB associated with elevated urinary
lysine and lower urinary formate
49
Amniotic fluid from 33 women
who experienced PTL with-
out IAI; 40 women who
experienced PTL with IAI;
40 women with control
delivery
GC-LC-MS Metabolomic profiles differed among all
groups. Patients delivering preterm with-
out IAI had relative decrease in carbohy-
drates and amino acids, whereas those
with IAI had decreased carbohydrates but
increased amino acids.
52
CVF, cervical vaginal fluid; GC, gas chromatography; H-NMR, hydrogen nuclear magnetic resonance; IAI, intra-amniotic inflammation; LC, liquid chromatogra-
phy; LC-MS/MS, liquid chromatography tandem mass spectrometry; MS, mass spectrometry; NMR, nuclear magnetic resonance spectroscopy; PTB, preterm
birth; PTL, preterm labor; sPTB, spontaneous preterm birth; TOF, time of flight; UHPLC, ultra-high performance liquid chromatography.
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CYP3A inhibitors, such as clarithromycin, erythromycin,
and fluoxetine, are associated with altered nifedipine phar-
macokinetics.72,73 Genetic polymorphisms in the L-type
calcium channel (CANC1C and CACN1D) and the
large-conductance calcium and voltage-dependent potas-
sium channel ß1 subunit gene (KCNMB1) have been asso-
ciated with responsiveness and risk of cardiovascular side
effects in patients taking calcium channel blockers for
hypertension.74,75 However, to our knowledge, these var-
iants have not been studied in pregnant women.
Prostaglandin inhibitors, such as indomethacin, are also
effective for the acute treatment of preterm labor.71 Indo-
methacin is primarily metabolized by the CYP2C9 enzyme.
The CYP2C9*2 and *3 poor metabolizer haplotypes may
lead to decreased indomethacin clearance in 10–20% of
white patients and up to 6% of black patients.76 In addition,
the activity of CYP2C9 is increased during pregnancy,3 lead-
ing to increased clearance of indomethacin (14.56 5.5 L/h
vs. 6.5–9.8 L/h in nonpregnant subjects).77 Although it has
an increased risk of adverse maternal events,71 magnesium
sulfate is often used for tocolysis due to its neuroprotective
effect.78,79 To our knowledge, personalization of magnesium
sulfate therapy based on clinical, demographic, or pharma-
cogenomics has not been investigated.
The 17-alpha hydroxyprogesterone caproate (17-OHPC)
is indicated for the prevention of PTB in women with a his-
tory of singlet sPTB. As with other progestins, 17-OHPC is
metabolized by CYP3A enzymes.80 Only a few clinical stud-
ies with limited sample size have investigated the pharma-
cogenetics of 17-OHPC.81–84 Common polymorphisms in
CYP3A genes have not been associated with outcomes to
17-OHPC.81 Studies examining polymorphisms in the pro-
gesterone receptor have produced conflicting results.81,82 A
recent exome-wide study by the NICHD’s Genomics and
Proteomics Network for Preterm Birth Research group has
identified a number of genetic differences associated with
response to 17-OHPC, including genes associated with
breast cancer estrogen signaling and oxidoreductase activ-
ity.84 Additional, larger scaled studies are needed to further
identify factors influencing response to 17-OHPC.
Systems approaches to understanding PTB
As indicated above, single-level “omics” approaches have
been largely unsuccessful in identifying biomarkers and
drug targets associated with PTB. Systems pharmacology
approaches that integrate a variety of data types, provide
novel tools to probe the pathophysiology of PTB, and other
pregnancy-associated diseases. As shown in Figure 2, the
genomic, proteomic, and metabolomic changes observed in
various studies of PTB (Tables 2–4) can be combined to
detect pathways that are altered in PTB, such as the com-
plement cascade, inflammatory pathways, and coagulation
pathways. To fully elucidate the mechanism of PTB, more
detailed mechanistic pathway analyses are required.
Although some of these pathways can be adopted from
other therapeutic areas (e.g., inflammatory cascade), addi-
tional details may be needed to fully understand the con-
nection of these pathways to PTB pathogenesis. To this
end, data from animal or in vitro studies may prove central
to the development of systems models. For instance, ex
vivo mouse studies provide evidence that progesterone
may work, in part, to directly modulate uterine contractil-
ity.85 Additionally, impact of environmental or other exoge-
nous stressors on PTB may be incorporated (e.g., to
investigate mechanisms associated with increased risk of
PTB in women who smoke).
Challenges of translational pharmacology in obstetrics
Although systems pharmacology holds great promise in
helping understand complex diseases of pregnancy, a num-
ber of challenges must be overcome to fully realize its
worth. As in other areas of research, systems pharmacol-
ogy approaches in obstetrics requires comprehensive clini-
cal data from electronic medical records, data management
resources, and bioinformatics and statistical tools to cata-
log, integrate, and analyze data obtained from various sour-
ces and reported in numerous formats. As illustrated
above, appropriate study design is essential to identifying
and understanding factors associated with PTB and other
disorders of pregnancy. Conde-Agudelo et al.86 conducted
a meta-analysis evaluating the accuracy of proteomic and
metabolomics biomarkers to predict asymptomatic sPTB in
women with singleton pregnancies. None of the 30 novel
biomarkers identified in their meta-analysis of 72 studies,
including 89,768 women, were deemed clinically useful to
predict sPTB in asymptomatic singleton pregnancies. Het-
erogeneity among studies makes validation and integration
of results difficult. For instance, although higher amniotic
fluid concentrations of IL-6 have been found by a number
of studies to be a predictor of PTB, variability among study
methods has made it difficult to establish a quantitative cut-
off point.56
Overcoming sample size limitations: Biobanks
One challenge in analyzing high-dimensional data is the
number of subjects required to detect a statistically signifi-
cant difference. In addition, the Institute of Medicine guide-
lines recommend that a potential biomarker should be
studied in separate training, test, and validation cohorts.87
It is impracticable to recruit women prospectively into studies
of this magnitude. The recent explosion of perinatal bio-
banks, which collect biological specimens across pregnancy,
enables access to the longitudinal samples required for
these studies. These biobanks, especially when linked to
comprehensive clinical data, provide a rich data source for
understanding changes in gene and protein expression and
function across pregnancy.
Perinatal biobanks vary drastically in size and scope of
individuals enrolled. A survey of North American perinatal
biobanks from 2013–2015 evaluated the scope, clinical doc-
umentation, and biospecimens collected. Seven pregnancy
biobanks, including the Indiana University Building Blocks of
Pregnancy Biobank, the Mount Sinai School of Medicine Preg-
nancy Biobank, the Global Alliance to Prevent Prematurity and
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Stillbirth (GAPPS) repository, Baylor College of Medicine,
Washington University St. Louis (WIHSC), University of
Hawaii, and Lunenfeld-Tanenbaum Research Institute Sinai
Health System Research Centre for Women’s and Infants’
Health (RCWIH) BioBank responded to the survey.88 All of
the biobanks collected cord blood, placental specimens, and
maternal plasma at delivery. Several collect maternal whole
blood, serum, and/or plasma samples throughout preg-
nancy. Two collected urine and CVF. Women who had
adverse pregnancy outcomes were well represented in the
biobanks surveyed, with PTB, pre-eclampsia, and gesta-
tional diabetes each occurring in about 10% of enrollees.
Although these localized biobank efforts provide a
resource for translational research, the discordance among
methods used to collect samples and information compli-
cates efforts to combine data from various groups. For
instance, placental samples may be collected in RNALater,
formalin fixed, fresh frozen, or snap frozen in liquid nitrogen
and time to delivery may vary depending on the protocol.88
These variations may impact the stability of analytes, lead-
ing to discrepancies in downstream analyses. Additionally,
clinical and demographic variables collected by individual
biobanks, as well as the informatics infrastructure used to
store the data, are not uniform. Thus, the informatic
requirements for combining the data from these samples
may be overwhelming.
In an effort to overcome these difficulties, a number of
biobank consortia have been established. For instance, the
Preterm Birth Genome Project was established by the
World Health Organization in 2007 to pool resources from
GWAS studies of PTB.89 The Preterm Birth International
Collaborative (PREBIC) also has worked to collate data on
studies of PTB and to develop standard definitions and
practices for future studies.29,89,90 The Global Pregnancy
Collaboration (CoLab) is an international collaboration of
over 35 centers with data on over 300,000 pregnancies,
including biobanks containing 20,000 plasma, serum, and
DNA.91 The technological, organizational, and legal chal-
lenges of developing these consortia are burdensome.
However, large insight into the pathogenesis of disorders of
therapies can be gleaned by the increased access to data
and biological samples provided by these consortia.
Phenotype harmonization
The PTB is defined as birth before 37-weeks’ gestation.
This definition, based on a time point, encompasses a wide
variety of clinical syndromes with numerous pathophysiolo-
gies. The PTB may be due to multifetal gestation (12%),
severe fetal malformations, or death in utero (9%), iatro-
genic causes (20%), or sPTB (60%).89 Iatrogenic PTB
Figure 2 Complex pathophysiology of preterm birth (PTB). Systems pharmacology approaches can integrate data from genomic, prote-
omic, metabolomic, clinical, in vitro, and animal studies to improve understanding and optimize therapy for PTB.
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are medically indicated due to other comorbidities, including
pre-eclampsia, gestational diabetes, and fetal growth
restriction. Spontaneous PTB can be further classified into
PPROMs, in which membranes rupture at least 1 hour
before onset of labor at <37-weeks’ gestation, or spontane-
ous preterm labor, defined as regular contractions with cer-
vical changes <37-weeks’ gestation. Although PPROM and
spontaneous preterm labor have distinct pathophysiologies
and clinical presentations, studies of PTB often group them
into a single cohort. This may reduce the power of a study
to detect significant associations or prevent results from
being replicated. Thus, there a critical need for large, gen-
eralizable studies of women with well-defined phenotypes
to develop specific cutoff points of validated biomarker pan-
els. Consortia, such as PREBIC, are leading efforts to
develop minimal datasets for “omics” studies of PTB and to
mitigate issues surrounding the assimilation of data from
multiple studies.89,90 Clear definition of clinical phenotype is
also necessary to define the pharmacodynamic outcomes
of systems pharmacology models, which may incorporate a
variety of endpoints (e.g., uterine contraction, cervical dila-
tion, time to delivery, and gestational age at delivery).
Informatic and biostatistical resources
The progress in the application of omics technologies (e.g.,
genomics, proteomics, and metabolomics) has enabled the
high-throughput monitoring of a variety of biochemical sys-
tems and characterization of the pathophysiology of several
conditions to develop efficient prediction models for diag-
nostic application. However, the advancement is hindered
by challenges within and in between omics-domain data
integration where combining the experimental results on
molecular profiling from different omics platforms could be
the major concern for interpretation of changes and predic-
tion models.
A variety of approaches to combining metabolomics with
genomics and proteomics data have been developed based
on the biochemical pathway, network, ontology, and empirical-
correlation methods. Biochemical pathway analysis pro-
vides the users a way to explore whether molecular path-
ways or biochemical processes are associated with a
phenotype study based on the omics data. A novel pathway
analytical approach gene set enrichment analysis (GSEA)
that combines transcriptomics data with metabonomics
data was developed for interpreting genome-wide expres-
sion profile data.92 However, pathway analysis of genome-
wide profiling assume that genes and pathways are
independent of each other often suffers from missing cell-
specific information and incomplete annotations.93 Genetic
analysis of PTB was studied using pathway-based analysis
where curated genes and the genomewide approach were
used to identify the gene-gene interactions from a validated
set of genes.94
A number of bioinformatic tools have been developed to
combine data from genomic, proteomic, and metabolomic
studies to describe biological pathways or networks. SAM-
NetWeb, a web-based analytical tool, uses proteomics and
transcriptomics to identify the distinct and common pathways
among multiple experiments and visualize them in a single
interaction network.95 Another rapidly growing web-based
tool, Metscape2, also links metabolite data with other omics
data, such as proteomics and transcriptomics. Users can
enter the experimental data (collected from different path-
ways of metabolites, proteins, and genes) stored in distinct
Kyoto Encyclopedia of Genes and Genomes and Edinburgh
Human Metabolic Network databases and identify the acti-
vated or expressed profiling data, build, and analyze the
data into a common network.96 Empirical-correlation meth-
ods are helpful to integrate biochemical with other omics
data when domain knowledge is unavailable. Weighted gene
co-expression network analysis can be used to identify the
clusters of highly correlated genes based on various gene
screening methods that have a potential to recognize candi-
date biomarkers.97 Although these system biology tools
have been used in other domains, we are unaware of exam-
ples in which multiple types of omics data from preterm labor
studies have been systematically integrated.
Interpretation of high-dimensional data in pregnancy is
made even more complex by the need to integrate mater-
nal, fetal, and placental data. The majority of bioinformatic
tools is developed for studies of conditions, such as cancer
and neurodegenerative diseases, and is thus biased to
adult diseases. Therefore, they may not encompass pro-
cesses of normal fetal development and parturition. This
bias toward functional classification was demonstrated by
Edlow et al.98 through the evaluation of transcriptomic data-
sets of cell-free RNA in amniotic fluid obtained from second
trimester fetuses with aneuploidy (trisomy 21), hemody-
namic (twin to twin transfusion syndrome), and metabolic
(maternal obesity) complications and controls. Functional
analyses conducted by ingenuity pathway analysis (IPA)
and GSEA through the gene ontology database augmented
with fetal-specific gene sets cataloged by the Developmen-
tal Functional Annotation at Tufts (DFLAT),1 which catalogs
human fetal gene functions.99 Edlow et al.98 found that IPA
and GSEA/DFLAT analyses provided different, but largely
complementary, interpretations of the data. The IPA, a pro-
prietary software, provided a preferred user interface and
unique analysis tools, such as the Canonical Pathway and
Upstream Regulator Analysis, that allowed for improved
mechanistic insight. However, compared to GSEA/DFLAT,
IPA was more biased toward adult diseases, misclassifying
fetal cell proliferation assays as cancer pathways.98
CONCLUSIONS
Systems pharmacology provides a means to integrate
changes in the physiologic factors that affect drug disposi-
tion and the complex interplay among maternal, placental,
and fetal systems and improve our understanding of the
pathophysiology and molecular mechanisms of disorders of
pregnancy, such as PTB. However, there are many chal-
lenges that need to be overcome to fully harness the potential
of systems pharmacology in obstetrics, including harmoniza-
tion of phenotype definitions and standardized methods of
annotation and analysis. As clinical studies in pregnant
women are often limited by ethical and practical constraints,
Systems Pharmacology in Pregnancy
Quinney et al.
79
www.psp-journal.com
other sources of data are important to consider (e.g., stud-
ies in other therapeutic areas, in vitro, or animal models).
Systems pharmacology approaches to integrate knowledge
of the physiologic and molecular mechanisms responsible
for normal and adverse outcomes of pregnancy may detect
new therapeutic targets for PTB and other pregnancy-
associated disorders. In addition, systems pharmacology
approaches that integrate the effect of pregnancy on phar-
macokinetics (e.g., through PBPK modeling) and pharma-
codynamic effects of drugs will better inform therapeutic
approaches and optimize dosing regimens in pregnancy.
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